---

Drugs for Liver Failure & Biliary Management - Katzung (16th Ed.)

1. HEPATIC CIRRHOSIS - Diuretics

Drugs and Their Use

• Overly aggressive diuresis causes intravascular volume depletion, hypokalemia, metabolic alkalosis
• Can precipitate hepatorenal syndrome and hepatic encephalopathy
• Aldosterone antagonists risk serious hyperkalemia in patients with even mild renal insufficiency

---

2. BILE ACID AGENTS (Biliary Management)

A. Ursodiol (Ursodeoxycholic acid)

• Pharmacokinetics: Orally absorbed; conjugated in liver with glycine or taurine; excreted in bile; undergoes extensive enterohepatic recirculation; t1/2 ~100 hours; with chronic use constitutes 30-50% of the bile acid pool.
• Mechanism:
  • Reduces hepatic cholesterol secretion → reduces cholesterol content of bile
  • Stabilizes hepatocyte canalicular membranes
  • Reduces concentrations of toxic endogenous bile acids
  • Has anti-inflammatory effects
• Clinical uses:
  1. Dissolution of small cholesterol gallstones in poor surgical candidates (dose: 10 mg/kg/d; takes 6-12 months)
  2. First-line treatment of primary biliary cirrhosis (PBC) (dose: 13-15 mg/kg/d) - improves liver biochemistry, slows histologic progression, reduces need for transplantation, improves survival. ~35% of patients do not respond.
• Adverse effects: Practically free of serious effects. Bile salt-induced diarrhea uncommon. No hepatotoxicity (unlike its predecessor chenodeoxycholic acid).

B. Obeticholic Acid (Ocaliva)

• Type: Synthetic derivative of chenodeoxycholic acid
• Mechanism:
  • Nontoxic bile acid that decreases hepatic concentrations of toxic endogenous bile acids
  • Ligand for the farnesoid X receptor (FXR) - modulates hepatic inflammation, fibrosis, gluconeogenesis, lipid synthesis, and insulin sensitivity
• Clinical uses:
  1. PBC: 5-10 mg/d orally, in combination with ursodiol, in patients with inadequate ursodiol response. ~50% clinical response vs. 10% with ursodiol alone in trials.
  2. Being evaluated for non-alcoholic steatohepatitis (NASH) - 25 mg/d for 18 months showed significant improvement in fibrosis (not yet FDA-approved for NASH).
• Adverse effects: Severe pruritus in up to 25% of patients (especially at 10 mg dose); leads to discontinuation in ~10%.

---

3. DRUGS USED TO TREAT VARICEAL HEMORRHAGE

A. Somatostatin & Octreotide

• Mechanism: Reduce portal blood flow and variceal pressures, likely via inhibition of glucagon and other gut peptides that regulate mesenteric blood flow (not direct vascular smooth muscle contraction)
• Use: Active variceal hemorrhage - administered for 3-5 days
• Dosing: Somatostatin 250 mcg/h IV; Octreotide 50 mcg/h IV

B. Vasopressin & Terlipressin

• Vasopressin: Potent arterial vasoconstrictor → splanchnic arterial vasoconstriction → reduced portal venous pressures. Largely replaced by octreotide due to serious adverse effects (hypertension, MI, mesenteric infarction, hyponatremia). May be combined with nitroglycerin to reduce coronary/peripheral vasospasm and further lower portal pressure.
• Terlipressin: Vasopressin analog; similar efficacy, fewer adverse effects; available in other countries but not FDA-approved in the USA.

C. Non-selective Beta-blockers (Propranolol, Nadolol)

• Mechanism: Reduce portal inflow via:
  • Beta-1 blockade → reduced cardiac output
  • Beta-2 blockade → splanchnic vasoconstriction (unopposed alpha effect on catecholamines)
• Uses:
  • Primary prophylaxis: In cirrhosis with esophageal varices, reduces bleeding incidence from 25% to 15%
  • Secondary prophylaxis: Reduces recurrent hemorrhage (recurrence otherwise ~80% within 2 years)
• Note: Selective beta-1 blockers are less effective than nonselective agents for this indication.

---

OTHER DRUGS IN THESE CLASSES (Beyond Katzung's Highlighted Agents)

Bile Acid / FXR-related Agents

Vasopressin Analogs (Variceal Hemorrhage/Portal Hypertension)

Aldosterone Antagonists (Diuretics in Liver Disease)

Vaptans (V2 Receptor Antagonists) - Hyponatremia in Cirrhosis

Somatostatin Analogs (for Portal Hypertension)

---

• In hepatic cirrhosis-associated ascites, spironolactone is preferred over loop diuretics due to the heightened aldosterone state. Loop diuretics are used as add-ons.
• Ursodiol is the cornerstone of PBC management; obeticholic acid is added when ursodiol fails.
• For acute variceal hemorrhage, octreotide has largely replaced vasopressin; non-selective beta-blockers are used for primary and secondary prophylaxis of variceal bleeding.
• Vaptans must be used carefully in liver disease - avoid in active hepatitis, may be useful in burned-out cirrhosis with hyponatremia.

---

Liver Failure & Biliary Management - Full Detail (Katzung 16e)

---

PART 1: HEPATIC CIRRHOSIS - ASCITES & EDEMA

Pathophysiology (Why These Drugs Are Chosen)

1. Elevated portal hydrostatic pressure - sinusoidal fibrosis, blocked venous outflow
2. Reduced plasma oncotic pressure - hypoalbuminemia (impaired synthesis)
3. Renal sodium retention - from diminished renal perfusion, diminished plasma volume, and critically - primary aldosterone excess (liver fails to metabolize aldosterone)

---

A. Aldosterone Receptor Antagonists - FIRST LINE

Spironolactone

• Class: Non-selective mineralocorticoid receptor (MR) antagonist
• Mechanism: Competes with aldosterone at renal distal tubule and collecting duct receptors → inhibits ENaC insertion → natriuresis without potassium loss
• Why it excels in cirrhosis: Cirrhotic edema is unusually responsive because the root cause is hyperaldosteronism. Loop diuretics fail partly because they can't overcome the high aldosterone state; spironolactone strikes directly at it.
• Adverse effects:
  • Hyperkalemia - major risk in patients with even mild renal insufficiency; Katzung explicitly says: "considerable caution is necessary"
  • Gynecomastia, menstrual irregularities, impotence - due to anti-androgenic and progestogenic effects (it also blocks androgen and progesterone receptors)

Eplerenone

• Class: Selective MR antagonist only
• Mechanism: Same as spironolactone but no anti-androgenic/progestogenic receptor binding
• Advantage: No gynecomastia or hormonal side effects
• Use: Alternative to spironolactone in cirrhosis; similar efficacy for ascites

---

B. Loop Diuretics - SECOND LINE (Adjunct)

Furosemide

• Class: Loop diuretic; inhibits Na+/K+/2Cl- cotransporter (NKCC2) in the thick ascending limb of Henle
• Why resistance occurs in cirrhosis:
  1. Hypoalbuminemia reduces drug delivery to tubular fluid (furosemide is protein-bound; it reaches the tubule via secretion)
  2. High circulating aldosterone counteracts the natriuresis
• Role: Adjunct to spironolactone; standard practice ratio is spironolactone 100 mg : furosemide 40 mg to maintain normokalemia
• Katzung's critical warning - consequences of overly aggressive diuresis in cirrhosis:
  • Intravascular volume depletion → hepatorenal syndrome (acute kidney injury)
  • Hypokalemia + metabolic alkalosis → hepatic encephalopathy (ammonia production increases with alkalosis)
  • This is worse than in heart failure - "even more disastrous"

---

C. Vaptans - Vasopressin V2-Receptor Antagonists (FOR HYPONATREMIA)

Tolvaptan

• Class: Selective V2-receptor antagonist ("aquaretic")
• Mechanism: Blocks V2 receptors in renal collecting ducts → prevents cAMP-mediated aquaporin-2 channel insertion → free water excretion without sodium loss
• Use in cirrhosis (Katzung's nuanced guidance):
  • Contraindicated/extreme caution in active hepatitis - high-dose tolvaptan caused transaminase elevations in an ADPKD trial
  • Potentially useful in burned-out cirrhosis (no ongoing liver damage) with hyponatremia or fluid overload
  • Studies show: reduced need for albumin infusion + decreased ascites accumulation in decompensated cirrhosis
  • Summary: avoid in active liver damage; may benefit end-stage cirrhosis with hyponatremia

---

PART 2: BILIARY MANAGEMENT - BILE ACID AGENTS

A. Ursodiol (Ursodeoxycholic Acid - UDCA)

Pharmacokinetics

Pharmacodynamics

1. Reduces hepatic cholesterol secretion → less cholesterol in bile → stones dissolve/prevented
2. Stabilizes hepatocyte canalicular membranes - by reducing concentration of toxic endogenous bile acids or inhibiting immune-mediated hepatocyte destruction
3. Anti-inflammatory effects on biliary epithelium
4. Replaces toxic hydrophobic bile acids (chenodeoxycholic, deoxycholic acid) with the nontoxic hydrophilic ursodiol

Clinical Uses

Adverse Effects

• Practically free of serious adverse effects
• Bile salt-induced diarrhea: uncommon
• No hepatotoxicity - unlike chenodeoxycholic acid, its historical predecessor (which caused hepatotoxicity and diarrhea, leading to its abandonment)

---

B. Obeticholic Acid (Ocaliva) - FXR Agonist

Mechanism (Two-Pronged)

1. Bile acid replacement - reduces hepatic concentrations of more toxic endogenous bile acids (same principle as ursodiol)
2. FXR nuclear receptor activation - obeticholic acid is a potent FXR ligand. FXR is a nuclear receptor expressed in liver, intestine, kidney, and adrenals. FXR activation:
   • Reduces bile acid synthesis (via FGF19 signaling → suppresses CYP7A1 and CYP8B1)
   • Reduces hepatic inflammation
   • Reduces fibrosis (suppresses hepatic stellate cell activation)
   • Modulates gluconeogenesis, lipid synthesis, and insulin sensitivity

Clinical Uses

Adverse Effects

• Pruritus (severe) in up to 25% of patients, especially at 10 mg
• Discontinuation due to pruritus: ~10% of patients
• Risk of hepatic decompensation if used in advanced cirrhosis (Child-Pugh B/C patients) - use with reduced dosing frequency

---

PART 3: VARICEAL HEMORRHAGE - PORTAL HYPERTENSION DRUGS

Pathophysiology

• Portal hypertension = increased portal blood flow (from splanchnic vasodilation due to excess NO, glucagon) + increased intrahepatic resistance (fibrosis + reversible sinusoidal vasoconstriction)
• Leads to portosystemic collaterals - esophageal/gastric varices → rupture → massive GI hemorrhage

---

A. Somatostatin & Octreotide

Octreotide

• Class: Synthetic somatostatin analog (8 amino acid cyclic peptide)
• Mechanism in portal hypertension:
  • Reduces portal blood flow and variceal pressures
  • Does not directly contract vascular smooth muscle
  • Mechanism likely: inhibition of glucagon and other vasoactive gut peptides that increase mesenteric blood flow
  • Binds SSTR2 and SSTR5 receptors → inhibits cAMP generation → reduced peptide release
• Dose: 50 mcg/h IV continuous infusion for 3-5 days
• Efficacy: Probably effective for initial hemostasis from bleeding esophageal varices (clinical trial data conflicting, but generally used as standard of care alongside endoscopic therapy)
• Clinical note: Used in combination with endoscopic band ligation or sclerotherapy - the drug is not curative alone

---

B. Vasopressin & Terlipressin

Vasopressin

• Class: Endogenous polypeptide; V1a + V2 receptor agonist
• Mechanism: V1a activation → potent splanchnic arterial vasoconstriction → reduced splanchnic perfusion → lower portal venous pressure
• Current status for varices: NO longer used for variceal hemorrhage - replaced by octreotide
• Current role: Intra-arterial infusion via angiographically placed catheter for bleeding from small/large bowel vascular ectasias or diverticulosis
• Adverse effects (reason for abandonment in variceal bleeding):
  • Hypertension, myocardial ischemia, myocardial infarction, mesenteric infarction (systemic vasoconstriction)
  • Hyponatremia, fluid overload, pulmonary edema (V2-mediated antidiuresis)
  • Nausea, cramps, diarrhea
  • Mitigation: Co-administer nitroglycerin to reduce coronary/peripheral vasospasm AND further reduce portal pressure (by lowering portohepatic vascular resistance)

Terlipressin

• Class: Synthetic vasopressin analog (V1a agonist prodrug - triglycyl-lysine vasopressin)
• Mechanism: Slowly converted to active lysine vasopressin in vivo → selective V1a splanchnic vasoconstriction; more gradual release = fewer cardiovascular spikes
• Uses:
  • Variceal hemorrhage (outside USA)
  • Hepatorenal Syndrome Type 1 (HRS-1) - FDA approved in USA in 2022 for HRS
• Advantages over vasopressin: Similar efficacy, significantly fewer cardiovascular adverse effects

---

C. Non-selective Beta-blockers - PROPHYLAXIS

Propranolol & Nadolol

• Class: Non-selective beta-1 + beta-2 antagonists
• Mechanism of portal pressure reduction:
  1. Beta-1 blockade → reduced cardiac output → reduced portal blood flow
  2. Beta-2 blockade → splanchnic vasoconstriction (unopposed alpha-adrenergic tone from circulating catecholamines acts on mesenteric vessels)
• Why selective beta-1 blockers (metoprolol, atenolol) are less effective: They miss the beta-2-mediated splanchnic vasoconstriction - so they reduce cardiac output but don't constrict the mesenteric vessels
• Clinical evidence:
  • Primary prophylaxis: In patients with cirrhosis + esophageal varices (never bled), reduces hemorrhage risk from 25% → 15%
  • Secondary prophylaxis: After a first bleed, recurrence rate without treatment = 80% within 2 years. Non-selective beta-blockers significantly reduce recurrent hemorrhage (reduction in mortality is less clear)
• Nadolol vs propranolol: Nadolol has longer half-life; once-daily dosing; similar efficacy

---

PART 4: HEPATIC ENCEPHALOPATHY

A. Lactulose - FIRST LINE

• Class: Synthetic non-absorbable disaccharide (galactose + fructose)
• Mechanism - multi-step:
  1. Not absorbed in the small intestine; reaches the colon intact
  2. Colonic bacteria ferment lactulose → lactic acid + acetic acid → colonic acidification (pH drops from ~7 to ~5)
  3. At acidic pH, NH3 (lipid-soluble, absorbable) is converted to NH4+ (ionized, non-absorbable) → ammonia trapped in stool
  4. Osmotic laxative effect → accelerated intestinal transit → less time for ammonia production and absorption
  5. May alter colonic flora composition (reduces ammonia-generating bacteria)
• Dose: 15-45 mL orally 2-4 times daily; titrate to 2-3 soft stools/day; rectal enema for obtunded patients
• Adverse effects: Flatulence, cramping, diarrhea; excessive use → dehydration, electrolyte disturbances

---

B. Rifaximin - FIRST LINE (Combination/Second Line)

• Class: Rifamycin derivative; poorly absorbed GI antibiotic
• Mechanism: Inhibits the beta subunit of bacterial DNA-dependent RNA polymerase → bactericidal against ammonia-producing gut bacteria (gram-positive + gram-negative aerobes and anaerobes)
• Why it works without systemic toxicity:
  • Systemic absorption: <0.5% orally
  • Fecal concentrations: up to 8000 mcg/g (high enough to kill gut bacteria)
  • NO CYP450-mediated drug interactions (unlike rifampin/rifabutin) due to negligible systemic levels
• Dose: 550 mg orally twice daily for hepatic encephalopathy
• Additional uses: Travelers' diarrhea (300 mg TID × 3 days); IBS-D; adjunct in recurrent C. difficile
• Comparison to neomycin: Vastly safer - no nephrotoxicity, no ototoxicity

---

C. Neomycin - Historical/Rarely Used

• Class: Aminoglycoside antibiotic
• Mechanism: Suppresses coliform (ammonia-producing) flora → reduces gut ammonia production
• Dose: 1 g every 6-8 hours orally, with reduced protein intake
• Status: Largely supplanted by lactulose and rifaximin
• Why abandoned: Nephrotoxicity + ototoxicity (auditory > vestibular); even oral neomycin is partially absorbed in patients with inflamed/diseased gut mucosa. Deafness may occur, especially with impaired renal function.

---

PART 5: HEPATOPROTECTIVE AGENT - SILYMARIN (Milk Thistle)

• Source: Silybum marianum (milk thistle)
• Active components: Silymarin (mixture: silybin A/B, silydianin, silychristin)
• Proposed mechanisms:
  1. Antioxidant: reduces lipid peroxidation, scavenges free radicals, enhances glutathione and superoxide dismutase
  2. Membrane stabilization → reduces toxin entry into hepatocytes
  3. Anti-inflammatory: inhibits lipoxygenase → reduces leukothriene formation; inhibits leukocyte migration; inhibits NF-kB (a key inflammatory mediator activated in NAFLD, alcoholic hepatitis, viral hepatitis, biliary disease)
  4. Antifibrotic: reduces collagen accumulation; reduces TGF-beta in hepatic stellate cells
  5. Increases RNA polymerase I activity in healthy hepatocytes (not malignant) → potential for hepatocyte regeneration
  6. Dose-dependent bile flow stimulation → potentially beneficial in cholestasis
• Clinical evidence: Systematic review of 13 RCTs (915 patients) found no significant reductions in all-cause mortality, liver histology, or complications. Insufficient evidence to recommend for clinical use.
• Studied in: Viral hepatitis (B, C), alcoholic liver disease, drug/toxin-induced liver injury

---

COMPLETE REFERENCE TABLE